EUVIMEDEUVIMED entdecken
Crossref

Emicizumab enhances the ex vivo coagulant potential in plasma samples from patients with von Willebrand disease

Mutsumi Yabe, Shoko Furukawa, Masahiro Takeyama, Kana Sasai, Naruto Shimonishi, Yuto Nakajima, Kenichi Ogiwara, Keiji Nogami

International Journal of Hematology · 2025

DOI: 10.1007/s12185-025-04098-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Hematology, 2025. Verfasst von Mutsumi Yabe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Medicine, Nara Medical University, Kashihara, Nara, Japan. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Blood Coagulation, von Willebrand Diseases. Die Arbeit nennt 44 Literaturangaben. Gefördert von: Grant-in-Aid for Scientific Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: von Willebrand disease (VWD) is a hereditary bleeding disorder caused by quantitative or qualitative deficiencies in von Willebrand factor (VWF). Our previous studies demonstrated that emicizumab, a bispecific monoclonal antibody that mimics activated factor VIII (FVIII) cofactor activity, enhances thrombus formation under high-shear conditions in whole blood from patients with VWD (PwVWD). However, its effect on plasma coagulation potential remains unclear. AIM: To evaluate the coagulation-enhancing effect of emicizumab in plasma samples from PwVWD using global coagulation assays. METHODS: Plasma samples from PwVWD (type 1, n = 4; type 2, n = 9; type 3, n = 3) were spiked with emicizumab (50 or 100 µg/mL), recombinant VWF (rVWF; 2.4 U/mL), or plasma-derived FVIII/VWF concentrate (pd-FVIII/VWF; 1/2.4 U/mL). Coagulation potential was assessed using clot waveform analysis (Ad|min1|) and thrombin generation assay (Peak-Th). RESULTS: Emicizumab dose-dependently increased Ad|min1| in all type 1 VWD samples and improved Peak-Th in two cases. In type 2 VWD, Ad|min1| increased in all samples, while Peak-Th improved in six cases. In type 3 VWD, emicizumab increased both parameters in all cases. CONCLUSION: Emicizumab enhanced ex vivo coagulation potential in plasma samples from PwVWD across all subtypes, supporting its potential as a therapeutic option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificAntibodies, Monoclonal, HumanizedBlood Coagulationvon Willebrand DiseasesHumansMaleBlood Coagulation Testsvon Willebrand FactorFemaleMiddle AgedAdultFactor VIII

Stichwörter der Autor:innen

Bispecific antibodyCoagulationMonitoringVon Willebrand diseaseVon Willebrand factor

Substanzen

Antibodies, BispecificemicizumabAntibodies, Monoclonal, Humanizedvon Willebrand FactorFactor VIII

Autor:innen und Institutionen

  • Graduate School of Medicine, Nara Medical University, Kashihara, Nara, Japan.
  • Department of Pediatrics, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan.
  • Division of Hemophilia, National Hospital Organization, Osaka National Hospital, Osaka, Japan.
  • Department of Pediatrics, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. mtake@naramed-u.ac.jp.
  • Division of Hemophilia, National Hospital Organization, Osaka National Hospital, Osaka, Japan. mtake@naramed-u.ac.jp.
  • The Course of Thrombosis and Hemostasis Molecular Pathology, Nara Medical University, Kashihara, Nara, Japan.

Förderung

  • Grant-in-Aid for Scientific Research

Zitieren

APA

Yabe, M., Furukawa, S., Takeyama, M., Sasai, K., Shimonishi, N., Nakajima, Y., Ogiwara, K., & Nogami, K. (2025). Emicizumab enhances the ex vivo coagulant potential in plasma samples from patients with von Willebrand disease. International Journal of Hematology. https://doi.org/10.1007/s12185-025-04098-7

Vancouver

Yabe M, Furukawa S, Takeyama M, Sasai K, Shimonishi N, Nakajima Y, et al. Emicizumab enhances the ex vivo coagulant potential in plasma samples from patients with von Willebrand disease. International Journal of Hematology. 2025. doi:10.1007/s12185-025-04098-7

BibTeX
@article{Yabe2025,
  author = {Yabe, Mutsumi and Furukawa, Shoko and Takeyama, Masahiro and Sasai, Kana and Shimonishi, Naruto and Nakajima, Yuto and Ogiwara, Kenichi and Nogami, Keiji},
  title = {Emicizumab enhances the ex vivo coagulant potential in plasma samples from patients with von Willebrand disease},
  journal = {International Journal of Hematology},
  year = {2025},
  doi = {10.1007/s12185-025-04098-7}
}
Kostenlos starten →